Moleculin Engages IQVIA to Manage Potential COVID-19 Clinical Trial
Go back to Moleculin Engages IQVIA to Manage Potential COVID-19 Clinical Trial| (NYSE: IQV) | Delayed: 261.75 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $261.75 | 52 Week High | $ | |||
| Open | $261.75 | 52 Week Low | $ | |||
| Day High | $261.75 | P/E | N/A | |||
| Day Low | $261.75 | EPS | $ | |||
| Volume | 83 | |||||
| METABASIS THERAPEUT (NASDAQ: MBRX) | Delayed: 0.65 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.65 | 52 Week High | $9.58 | |||
| Open | $0.65 | 52 Week Low | $2.34 | |||
| Day High | $0.65 | P/E | N/A | |||
| Day Low | $0.65 | EPS | $-0.34 | |||
| Volume | 6,535 | |||||
